Vicore Pharma Holding Company Profile - aVenture Research
Vicore Pharma Holding
A clinical-stage biopharmaceutical company, Vicore Pharma Holding develops buloxibutid, an angiotensin II type 2 receptor agonist evaluated in IPF patients.
Vicore Pharma Holding is a clinical-stage biopharmaceutical company developing a new class of oral angiotensin II type 2 receptor agonists with disease-modifying potential in respiratory and fibrotic diseases, led by buloxibutid for idiopathic pulmonary fibrosis. The company began from the design and synthesis of buloxibutid by Professor Anders Hallberg's group at Uppsala University. Vicore works in diseases where the angiotensin II type 2 receptor has a central role in stopping and reversing disease pathology.
Buloxibutid is a first-in-class drug that is orally available and low in molecular weight. It targets the underlying fibrosis in idiopathic pulmonary fibrosis by stimulating the protective arm of the renin-angiotensin system, and this mechanism produces an upstream effect that promotes alveolar repair and maintenance of alveolar integrity, reduces fibrosis formation, and stabilizes disease. Buloxibutid has been evaluated in patients with idiopathic pulmonary fibrosis.